



**UNIKLINIK
KÖLN**

Prospective study of the E-liac stent graft system in patients
with common iliac artery aneurysm: 12-months results



**Jan Brunkwall on behalf of the
PLIANT study group**



JOTEC, Hechingen, Germany

Prospective, European, observational study

45 patients

11 centers

3 years follow-up

Corelab





Study center	Investigator	Patients (n45)
Valladolid	Carlos Vaquero Puerta	7
Köln		6
Osnabrück	Heckenkamp	5
Kiel	Schäfer	5
Warszawa	Szopinski	5
San Sebastian	Barrenechea	5
Chemnitz	Seifert	4
Wien/Hietzing	Mertikian	4
Speyer	Rümenapf	2
Wien	Assadian	1
Berlin	Buz	1



Parameter

(n45)

Age (years mean \pm SD)

72 \pm 7

Male

42



Parameter	(n45)
Arterial hypertension	37
Cardiac Disease	
- yes	19
- unknown	1
Hyperlipidemia	24
Pulmonary disease	10
Renal Insufficiency	7
Diabetes	9
Dialysis	0



	Surgical	Percutaneous
Femoral access (left)	30	14
Femoral access (right)	31	14



E-liac implantation side	(n45)
--------------------------	-------

Right	28
-------	----

Left	14
------	----

Both	3
------	---

Contralateral internal iliac artery occluded*	10
---	----

* Planned perioperative occlusion of contralateral iliac artery. Patient only treated unilaterally with an E-liac Stent Graft.

Peripheral stent graft used	(n48)
E-ventus BX	36
Advanta V12	10
Bard LifeStream	1
Bentley BeGraft	1

One E-ventus BX Stent Graft was implanted in combination with one Bard LifeStream Vascular Covered Stent.



Distal landing area	(n48)
Main IIA trunk	45
Anterior IIA	1
Posterior IIA	2

Abdominal stent graft used

(n45)

E-vita abdominal XT (JOTEC)

8

E-tegra Stent Graft (JOTEC)

23

Endurant (Medtronic)

2

Endurant AUI (Medtronic)

1

Treovance (Bolton)

3

Ovation (Endologix)

1

Gore Excluder (Gore)

1



Overall clinical success	38
Primary clinical success without reintervention	31



7 endoleaks (except type II)


3 closed spontaneously until first post-op CT

3 endoleaks type Ia (Aortic)

1 endoleak in isolated IAA (mismatch)



1-year Results E-iliac (n48)



Nr. of E-liacs under observation and at risk

Time [days]	Nr. of E-liacs
0	48
30	48
60	45
90	45
120	45
140	44
180	44
210	42
240	42
270	40
300	39
330	38
360	33
420	21



Variable	0 -30 days	30 days - 12 months
	(N = 45)	(N = 42)
Reintervention		
Endovascular to correct Type Ia endoleak		
related to E-liac Stent Graft	1 (2%)	0 (0%)
related to AAA stent graft	0 (0%)	3 (7%)
Endovascular to correct Type II endoleak	0 (0%)	1 (2%)
Open surgery to correct thromboembolism/thrombosis		
related to E-liac Stent Graft	0 (0%)	1 (2%)
related to AAA stent graft	1 (2%)	0 (0%)
Endovascular to correct stenosis		
related to E-liac Stent Graft	1 (2%)	0 (0%)
related to AAA stent graft	0 (0%)	1 (2%)
Complications		
Transient buttock or thigh claudication	1 (2%)	1 (2%)
New buttock or thigh claudication	0 (0%)	1 (2%)
Buttock necrosis	0 (0%)	0 (0%)

90% clinical success at 1 year

4 successful reinterventions

1 lower limb intermittent claudication with
relation to the E-liac Stent Graft

3 without a relation to the E-liac Stent Graft

98% primary patency in IIA

98% primary patency in EIA





E-liac is:

Safe

Versatile

Effective

Problems encountered were man driven



Thank you very much for your attention!